Category: AstraZeneca
-
STAT+: Enhertu pushes into early breast cancer, as antibody-drug conjugates move up the line
STAT+: Enhertu pushes into early breast cancer, as antibody-drug conjugates move up the line BERLIN — Enhertu has become a staple treatment in advanced breast cancer, but new data presented Saturday at the European Society for Medical Oncology’s annual conference show the drug can have powerful benefits for patients when given earlier in the disease,…
-
Party in biotech land and AstraZeneca’s miscalculation
Party in biotech land and AstraZeneca’s miscalculation Where did former vaccine regulator Peter Marks find a new job? How did a math error cost AstraZeneca a rare disease candidate? And is biotech back? We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on Mizuho health care…
-
STAT+: AstraZeneca’s CEO balances cancer-fighting opportunities with political uncertainty
STAT+: AstraZeneca’s CEO balances cancer-fighting opportunities with political uncertainty CHICAGO — Each year, 40,000 cancer researchers, doctors, and industry executives gather here for the biggest meeting in oncology. And for seven years, it has been almost assumed that the medicines generating the most buzz will come from AstraZeneca. Perhaps that’s why, in a wood-paneled conference…
-
STAT+: Eli Lilly and AstraZeneca top a consultancy’s ranking of drug company R&D
STAT+: Eli Lilly and AstraZeneca top a consultancy’s ranking of drug company R&D A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap — but when it comes to invention, AstraZeneca, with its wealth of experimental cancer and rare disease therapies, ranks above its…
-
RSV sent fewer babies to the hospital last winter, after new treatment and vaccine arrived
RSV sent fewer babies to the hospital last winter, after new treatment and vaccine arrived A new report from the Centers for Disease Control and Prevention shows there was a substantial drop in hospitalizations for respiratory syncytial virus this winter among very young children, who are at the highest risk of becoming severely ill if they contract…